[Featured Stock] Access Bio's Self-Diagnostic Home Kit Receives US FDA Emergency Use Authorization...Surges Over 10%
![[Featured Stock] Access Bio's Self-Diagnostic Home Kit Receives US FDA Emergency Use Authorization...Surges Over 10%](http://www.asiae.co.kr/news/img_view.htm?img=2020110610243786827_1604625878.jpg)
[Asia Economy Reporter Ji-hwan Park] Access Bio is surging on news that it has received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) for its COVID-19 antigen home test kit.
As of 10:10 a.m. on the 4th, Access Bio is trading at 31,450 KRW, up 10.16% from the previous trading day.
The approved product is the 'CareStartTM COVID-19 Antigen Home Test.' With this approval, Access Bio's product can be purchased anywhere online or offline without a hospital prescription.
Hot Picks Today
"Only Two Per Person" Garbage Bag Crisis Was Just Yesterday... Japan Also Faces Shortage Anxiety
- "Samsung Electronics Employee with 100 Million Won Salary Receiving 600 Million Won Bonus... Estimated Tax Revealed"
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- 'Will Demand Finally Decline Due to High Prices?'... "I'll Just Enjoy Nearby Trips" as Japan and China See a Surge
- "Wore It Once, Then This? White Spots All Over 4.15 Million Won Prada Jacket... 'Full Refund Ordered'"
This product is characterized by its ability to quickly and easily detect infection within 10 to 15 minutes by collecting a sample from the nasal cavity using a swab. Anyone aged 14 or older can use it alone. Children under 14 can be tested with the help of an adult, making it highly versatile across all age groups.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
